메뉴 건너뛰기




Volumn 33, Issue 4, 2015, Pages 166.e9-166.e15

Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder

Author keywords

4E BP1; Invasive urothelial carcinoma of bladder; Ku 0063794; MTOR pathway

Indexed keywords

5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; EIF4EBP1 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

EID: 85006285307     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.12.006     Document Type: Article
Times cited : (12)

References (30)
  • 1
    • 84864616537 scopus 로고    scopus 로고
    • Contemporary management of muscle-invasive bladder cancer
    • Dall'Era M.A., Cheng L., Pan C.X. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2012, 12:941-950.
    • (2012) Expert Rev Anticancer Ther , vol.12 , pp. 941-950
    • Dall'Era, M.A.1    Cheng, L.2    Pan, C.X.3
  • 2
    • 84859435388 scopus 로고    scopus 로고
    • Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients
    • Hautmann R.E., de Petriconi R.C., Pfeiffer C., Volkmer B.G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012, 61:1039-1047.
    • (2012) Eur Urol , vol.61 , pp. 1039-1047
    • Hautmann, R.E.1    de Petriconi, R.C.2    Pfeiffer, C.3    Volkmer, B.G.4
  • 3
    • 33751057732 scopus 로고    scopus 로고
    • Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
    • Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006, 176:2414-2422.
    • (2006) J Urol , vol.176 , pp. 2414-2422
    • Shariat, S.F.1    Karakiewicz, P.I.2    Palapattu, G.S.3
  • 4
    • 84865287448 scopus 로고    scopus 로고
    • Current therapeutic strategies for invasive and metastatic bladder cancer
    • Vishnu P., Mathew J., Tan W.W. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 2011, 4:97-113.
    • (2011) Onco Targets Ther , vol.4 , pp. 97-113
    • Vishnu, P.1    Mathew, J.2    Tan, W.W.3
  • 5
    • 84859778293 scopus 로고    scopus 로고
    • MTOR signaling in growth control and disease
    • Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
    • (2012) Cell , vol.149 , pp. 274-293
    • Laplante, M.1    Sabatini, D.M.2
  • 7
    • 79957983577 scopus 로고    scopus 로고
    • Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs
    • Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
    • (2010) Oncotarget , vol.1 , pp. 530-543
    • Markman, B.1    Dienstmann, R.2    Tabernero, J.3
  • 8
    • 84874048152 scopus 로고    scopus 로고
    • Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
    • Tickoo S.K., Milowsky M.I., Dhar N., et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int 2011, 110:1237-1248.
    • (2011) BJU Int , vol.110 , pp. 1237-1248
    • Tickoo, S.K.1    Milowsky, M.I.2    Dhar, N.3
  • 9
    • 63049094489 scopus 로고    scopus 로고
    • Inactivation of p53 and PTEN promotes invasive bladder cancer
    • Puzio-Kuter A.M., Castillo-Martin M., Kinkade C.W., et al. Inactivation of p53 and PTEN promotes invasive bladder cancer. Genes Dev 2009, 23:675-680.
    • (2009) Genes Dev , vol.23 , pp. 675-680
    • Puzio-Kuter, A.M.1    Castillo-Martin, M.2    Kinkade, C.W.3
  • 10
    • 81055144867 scopus 로고    scopus 로고
    • S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer
    • Nawroth R., Stellwagen F., Schulz W.A., et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011, 6:e27509.
    • (2011) PLoS One , vol.6
    • Nawroth, R.1    Stellwagen, F.2    Schulz, W.A.3
  • 11
    • 84890791290 scopus 로고    scopus 로고
    • Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: effect on prognostic outcomes following radical nephrectomy
    • Nishikawa M., Miyake H., Harada K., Fujisawa M. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: effect on prognostic outcomes following radical nephrectomy. Urol Oncol 2014, 32. 49.(e15-21).
    • (2014) Urol Oncol , vol.32 , pp. 49+e15-e21
    • Nishikawa, M.1    Miyake, H.2    Harada, K.3    Fujisawa, M.4
  • 12
    • 0037441652 scopus 로고    scopus 로고
    • Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy
    • Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
    • (2003) J Clin Oncol , vol.21 , pp. 690-696
    • Madersbacher, S.1    Hochreiter, W.2    Burkhard, F.3
  • 13
    • 78650990540 scopus 로고    scopus 로고
    • The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases
    • Abou Youssif T., Fahmy M.A., Koumakpayi I.H., et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011, 117:290-300.
    • (2011) Cancer , vol.117 , pp. 290-300
    • Abou Youssif, T.1    Fahmy, M.A.2    Koumakpayi, I.H.3
  • 14
    • 6044223545 scopus 로고    scopus 로고
    • Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
    • Zhou X., Tan M., Stone Hawthorne V., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
    • (2004) Clin Cancer Res , vol.10 , pp. 6779-6788
    • Zhou, X.1    Tan, M.2    Stone Hawthorne, V.3
  • 15
    • 70049113978 scopus 로고    scopus 로고
    • Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
    • Dai B., Kong Y.Y., Ye D.W., Ma C.G., Zhou X., Yao X.D. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2012, 104:1009-1016.
    • (2012) BJU Int , vol.104 , pp. 1009-1016
    • Dai, B.1    Kong, Y.Y.2    Ye, D.W.3    Ma, C.G.4    Zhou, X.5    Yao, X.D.6
  • 16
    • 84896691995 scopus 로고    scopus 로고
    • The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma
    • Lee Y.J., Hah Y.J., Kang Y.N., et al. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One 2013, 8:e81540.
    • (2013) PLoS One , vol.8
    • Lee, Y.J.1    Hah, Y.J.2    Kang, Y.N.3
  • 17
    • 0035675829 scopus 로고    scopus 로고
    • Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model
    • Miyake H., Hara I., Kamidono S., Gleave M.E. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001, 7:4245-4252.
    • (2001) Clin Cancer Res , vol.7 , pp. 4245-4252
    • Miyake, H.1    Hara, I.2    Kamidono, S.3    Gleave, M.E.4
  • 18
    • 0028861211 scopus 로고
    • P53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder
    • Serth J., Kuczyk M.A., Bokemeyer C., et al. p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995, 71:201-205.
    • (1995) Br J Cancer , vol.71 , pp. 201-205
    • Serth, J.1    Kuczyk, M.A.2    Bokemeyer, C.3
  • 19
    • 84863442079 scopus 로고    scopus 로고
    • Current status of molecular markers for prognostication and outcome in invasive bladder cancer
    • Gakis G., Schwentner C., Todenhöfer T., Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012, 110:233-237.
    • (2012) BJU Int , vol.110 , pp. 233-237
    • Gakis, G.1    Schwentner, C.2    Todenhöfer, T.3    Stenzl, A.4
  • 20
    • 33750089285 scopus 로고    scopus 로고
    • Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
    • Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107:1801-1811.
    • (2006) Cancer , vol.107 , pp. 1801-1811
    • Castellvi, J.1    Garcia, A.2    Rojo, F.3
  • 21
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3
  • 22
    • 84863393353 scopus 로고    scopus 로고
    • Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
    • Gupta M., Hendrickson A.E., Yun S.S., et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012, 119:476-487.
    • (2012) Blood , vol.119 , pp. 476-487
    • Gupta, M.1    Hendrickson, A.E.2    Yun, S.S.3
  • 23
    • 84887022988 scopus 로고    scopus 로고
    • Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
    • Harada K., Miyake H., Kumano M., et al. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer 2013, 109:2389-2395.
    • (2013) Br J Cancer , vol.109 , pp. 2389-2395
    • Harada, K.1    Miyake, H.2    Kumano, M.3
  • 24
    • 84897033468 scopus 로고    scopus 로고
    • Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
    • Ducker G.S., Atreya C.E., Simko J.P., et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014, 33:1590-1600.
    • (2014) Oncogene , vol.33 , pp. 1590-1600
    • Ducker, G.S.1    Atreya, C.E.2    Simko, J.P.3
  • 25
    • 15044340650 scopus 로고    scopus 로고
    • Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin factor 4E-binding proteins
    • Wang X., Beugnet A., Murakami M., et al. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin factor 4E-binding proteins. Mol Cell Biol 2005, 25:2558-2572.
    • (2005) Mol Cell Biol , vol.25 , pp. 2558-2572
    • Wang, X.1    Beugnet, A.2    Murakami, M.3
  • 26
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 31:2271-2281.
    • (2007) N Engl J Med , vol.31 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 27
    • 34548028705 scopus 로고    scopus 로고
    • 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications
    • Armengol G., Rojo F., Castellví J., et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67:7551-7555.
    • (2007) Cancer Res , vol.67 , pp. 7551-7555
    • Armengol, G.1    Rojo, F.2    Castellví, J.3
  • 28
    • 34848901974 scopus 로고    scopus 로고
    • Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
    • Graff J.R., Konicek B.W., Vincent T.M., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007, 117:2638-2648.
    • (2007) J Clin Invest , vol.117 , pp. 2638-2648
    • Graff, J.R.1    Konicek, B.W.2    Vincent, T.M.3
  • 29
    • 49749125291 scopus 로고    scopus 로고
    • Targeting the eIF4F translation initiation complex for cancer therapy
    • Konicek B.W., Dumstorf C.A., Graff J.R. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 2008, 7:2466-2471.
    • (2008) Cell Cycle , vol.7 , pp. 2466-2471
    • Konicek, B.W.1    Dumstorf, C.A.2    Graff, J.R.3
  • 30
    • 80054114844 scopus 로고    scopus 로고
    • A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
    • Hong D.S., Kurzrock R., Oh Y., et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011, 17:6582-6591.
    • (2011) Clin Cancer Res , vol.17 , pp. 6582-6591
    • Hong, D.S.1    Kurzrock, R.2    Oh, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.